Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history
Author:
Open Access
- 24 April 2023
- journal article
- review article
- Published by Wiley in European Journal of Immunology
- Vol. 53 (7) , e2249941
Abstract
The first worldwide article reporting that injections of synthetic nonreplicating mRNA could be used as a vaccine, which originated from a French team located in Paris, was published in the European Journal of Immunology (EJI) in 1993. It relied on work conducted by several research groups in a handful of countries since the 1960s, which put forward the precise description of eukaryotic mRNA and the method to reproduce this molecule in vitro as well as how to transfect it into mammalian cells. Thereafter, the first industrial development of this technology began in Germany in 2000, with the founding of CureVac, which stemmed from another description of a synthetic mRNA vaccine published in EJI in 2000. The first clinical studies investigating mRNA vaccines in humans were performed as collaboration between CureVac and the University of Tübingen in Germany as early as 2003. Finally, the first worldwide approved mRNA vaccine (an anti‐COVID‐19 vaccine) is based on the mRNA technologies developed by BioNTech since its 2008 foundation in Mainz, Germany, and earlier by the pioneering academic work of its founders. In addition to the past, present, and future of mRNA‐based vaccines, the article aims to present the geographical distribution of the early work, how the development of the technology was implemented by several independent and internationally distributed research teams, as well as the controversies on the optimal way to design or formulate and administer mRNA vaccines.Keywords
This publication has 85 references indexed in Scilit:
- Nonviral delivery of self-amplifying RNA vaccinesProceedings of the National Academy of Sciences, 2012
- Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding ErythropoietinMolecular Therapy, 2012
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011
- Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNAScience, 1992
- A very mild method allowing the encapsulation of very high amounts of macromolecules into very large (1000 nm) unilamellar liposomesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1983
- Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytesNature, 1978
- Evidence for translation of rabbit globin mRNA after liposomemediated insertion into a human cell lineNature, 1978
- Influence of bacterial ribonucleic acid on animal cells in cultureExperimental Cell Research, 1963
- Synthesis of ‘Bacterial’ Protein by Cultured Chick CellsNature, 1962
- Genetic regulatory mechanisms in the synthesis of proteinsJournal of Molecular Biology, 1961